Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

Excluding these special items, adjusted loss per share was 72 cents compared with a loss of 85 cents per share in the ...

Following the game-changing success of Spinraza, a molecular-based therapy that was crucial in the treatment of SMA (Spinal Muscular Atrophy), which used to be one of the leading genetic killers of ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of ...

In the third quarter, lower sales of multiple sclerosis (“MS”) drugs and spinal muscular atrophy drug, Spinraza, are likely to have been partially offset by revenues from new drugs.

Spinraza from Biogen and Evrysdi from Roche can prevent motor neurons from quitting, but they don't do anything to help rebuild muscle. The Sapphire study enrolled 156 patients ages 2 through 12 ...

Evrysdi is the third treatment approved for SMA, an ultra-rare muscle wasting disease that can begin in early childhood, after Biogen’s Spinraza (nusinersen) and Novartis’ Zolgensma ...

The firm expanded its neurology portfolio beyond MS, including the blockbuster Spinraza for spinal muscular atrophy, or SMA, a rare neuromuscular disease. We see Biogen as a firm in transition ...

SKYCLARYS Revenue: $82 million in the US, $102 million globally, with increased demand. SPINRAZA Revenue: $381 million, declined 15% due to loss of an annual tender in Russia. ZURZUVAE Revenue: $22 ...

In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.